{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:03:04Z","timestamp":1792803784008,"version":"4.5.0"},"reference-count":51,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"QUALIblood s.a"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the impact on thrombin generation of the new combined oral contraceptive containing 15\u2005mg estetrol and 3\u2005mg drospirenone with ethinylestradiol (30 or 20\u2005mcg) associated either with 150\u2005mcg levonorgestrel or with 3\u2005mg drospirenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected from the \u201cE4\/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\u201d (NCT02957630). Overall, the per-protocol set population included 24 subjects in the ethinylestradiol\/levonorgestrel arm, 28 subjects in the ethinylestradiol\/drospirenone arm, and 34 subjects in the estetrol\/drospirenone arm. Thrombograms and thrombin generation parameters (lag time, peak, time to peak, endogenous thrombin potential, and mean velocity rate index) were extracted for each subject at baseline and after 6 cycles of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 cycles of treatment, ethinylestradiol-containing products arms show a mean thrombogram outside the upper limit of the reference range, that is the 97.5th percentile of all baseline thrombograms. On the other hand, the mean thrombogram of estetrol\/drospirenone is within this reference interval. After 6 cycles of treatment, all thrombin generation parameters are statistically less affected by estetrol\/drospirenone than ethinylestradiol-containing products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, an association of 15\u2005mg estetrol with 3\u2005mg drospirenone does not have an impact on thrombin generation compared with ethinylestradiol-containing products that, either associated with levonorgestrel or drospirenone, are able to increase the production of procoagulant factors and decrease the production of anticoagulant ones, shifting the patient to a prothrombotic state. Ethinylestradiol-containing products thus generate prothrombotic environments contrary to estetrol which demonstrates a neutral profile on hemostasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac511","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T15:14:06Z","timestamp":1663082046000},"page":"135-143","source":"Crossref","is-referenced-by-count":43,"title":["Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-304X","authenticated-orcid":false,"given":"Laure","family":"Morimont","sequence":"first","affiliation":[{"name":"Research Department, Qualiblood sa , 5000 Namur , Belgium"},{"name":"Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Clinical Pharmacology Research Group, University of Namur , 5000 Namur , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Jost","sequence":"additional","affiliation":[{"name":"Estetra SRL, An Affiliate\u2019s Company of Mithra Pharmaceuticals , Li\u00e8ge, 4020 Li\u00e8ge , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulysse","family":"Gaspard","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Li\u00e8ge , 4000 Li\u00e8ge , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Foidart","sequence":"additional","affiliation":[{"name":"Estetra SRL, An Affiliate\u2019s Company of Mithra Pharmaceuticals , Li\u00e8ge, 4020 Li\u00e8ge , Belgium"},{"name":"University of Li\u00e8ge , 4000 Li\u00e8ge , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Clinical Pharmacology Research Group, University of Namur , 5000 Namur , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[{"name":"Research Department, Qualiblood sa , 5000 Namur , Belgium"},{"name":"Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Clinical Pharmacology Research Group, University of Namur , 5000 Namur , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"issue":"3","key":"2022121716483093200_dgac511-B1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.15608","article-title":"Venous thromboembolism and women's health","volume":"183","author":"Speed","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2022121716483093200_dgac511-B2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2008.02921.x","article-title":"Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study","volume":"6","author":"Pomp","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2022121716483093200_dgac511-B3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-years-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Internal Med"},{"issue":"3","key":"2022121716483093200_dgac511-B4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/AOG.0b013e31820ce2db","article-title":"Risk of venous thromboembolism during the postpartum period: a systematic review","volume":"117","author":"Jackson","year":"2011","journal-title":"Obstet Gynecol"},{"key":"2022121716483093200_dgac511-B5","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","volume":"3","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2022121716483093200_dgac511-B6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"2022121716483093200_dgac511-B7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"2022121716483093200_dgac511-B8","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"2022121716483093200_dgac511-B9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"2022121716483093200_dgac511-B10","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"2022121716483093200_dgac511-B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis","volume":"168","author":"Rovinski","year":"2018","journal-title":"Thromb Res"},{"issue":"8","key":"2022121716483093200_dgac511-B12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0040-1714140","article-title":"Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk","volume":"46","author":"Douxfils","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"2022121716483093200_dgac511-B13","doi-asserted-by":"crossref","first-page":"769187","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol"},{"key":"2022121716483093200_dgac511-B14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJM198109103051104","article-title":"Oral contraceptives and cardiovascular disease (first of two parts)","volume":"305","author":"Bruce","year":"1981","journal-title":"N Engl J Med"},{"key":"2022121716483093200_dgac511-B15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50\u2005\u00b5g or 30\u2005\u00b5g oestrogen","volume":"310","author":"Meade","year":"1977","journal-title":"Lancet"},{"issue":"4 Pt 2","key":"2022121716483093200_dgac511-B16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9378(87)80129-1","article-title":"Coagulation effects of oral contraception","volume":"157","author":"Bonnar","year":"1987","journal-title":"Am J Obstet Gynecol"},{"issue":"19","key":"2022121716483093200_dgac511-B17","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1001\/jama.1976.03270200017021","article-title":"Estrogen-containing oral contraceptives agents: a basis for their thrombogenicity","volume":"236","author":"Wessler","year":"1976","journal-title":"JAMA"},{"issue":"5-6","key":"2022121716483093200_dgac511-B18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2004.08.004","article-title":"Haemostatic changes in pregnancy","volume":"114","author":"Brenner","year":"2004","journal-title":"Thromb Res"},{"issue":"7","key":"2022121716483093200_dgac511-B19","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"Determinants of the APTT- and ETP-based APC sensitivity tests","volume":"3","author":"de Visser","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2022121716483093200_dgac511-B20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"Douxfils","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"2022121716483093200_dgac511-B21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2141.2007.06738.x","article-title":"Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence","volume":"138","author":"van Hylckama Vlieg","year":"2007","journal-title":"Br J Haematol"},{"issue":"10","key":"2022121716483093200_dgac511-B22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1538-7836.2009.03561.x","article-title":"Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study","volume":"7","author":"Lutsey","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2022121716483093200_dgac511-B23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/1354750X.2016.1204010","article-title":"Sex hormone-binding globulin and thrombin generation in women using hormonal contraception","volume":"22","author":"Hugon-Rodin","year":"2017","journal-title":"Biomarkers"},{"issue":"10","key":"2022121716483093200_dgac511-B24","doi-asserted-by":"crossref","first-page":"e0206376","DOI":"10.1371\/journal.pone.0206376","article-title":"The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index","volume":"13","author":"Mohamed","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"2022121716483093200_dgac511-B25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"issue":"2","key":"2022121716483093200_dgac511-B26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"Gerard","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1-2","key":"2022121716483093200_dgac511-B27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jsbmb.2008.03.027","article-title":"Estetrol: a unique steroid in human pregnancy","volume":"110","author":"Holinka","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"2022121716483093200_dgac511-B28","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.15252\/emmm.201404112","article-title":"The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation","volume":"6","author":"Abot","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"6","key":"2022121716483093200_dgac511-B29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"issue":"1","key":"2022121716483093200_dgac511-B30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2022121716483093200_dgac511-B31","volume-title":"Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline\u2014Third Edition. CLSI Document EP28-A3C","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"issue":"3","key":"2022121716483093200_dgac511-B32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1471-0528.1996.tb09716.x","article-title":"The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives","volume":"103","author":"Norris","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"2022121716483093200_dgac511-B33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1995","journal-title":"Lancet"},{"issue":"7305","key":"2022121716483093200_dgac511-B34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"issue":"7","key":"2022121716483093200_dgac511-B35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17512433.2020.1783247","article-title":"Drospirenone 4\u2005mg-only pill (DOP) in 24 + 4 regimen: a new option for oral contraception","volume":"13","author":"Del Savio","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"2022121716483093200_dgac511-B36","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/aogs.13688","article-title":"Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill","volume":"98","author":"Palacios","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2022121716483093200_dgac511-B37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled \u201cEstrogen and thrombosis: A bench to bedside review\u201d (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"issue":"11","key":"2022121716483093200_dgac511-B38","first-page":"562","article-title":"Use of calibrated automated thrombinography \u00b1 thrombomodulin to recognise the prothrombotic phenotype","volume":"96","author":"Negrier","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"2022121716483093200_dgac511-B39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2007.04.012","article-title":"The endogenous thrombin potential and the risk of venous thromboembolism","volume":"121","author":"Tripodi","year":"2007","journal-title":"Thromb Res"},{"issue":"8","key":"2022121716483093200_dgac511-B40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1538-7836.2008.03018.x","article-title":"High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism","volume":"6","author":"Tripodi","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2022121716483093200_dgac511-B41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jama.296.4.397","article-title":"Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation","volume":"296","author":"Hron","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"2022121716483093200_dgac511-B42","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1373\/clinchem.2008.112243","article-title":"Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer","volume":"54","author":"Eichinger","year":"2008","journal-title":"Clin Chem"},{"issue":"3","key":"2022121716483093200_dgac511-B43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"issue":"3","key":"2022121716483093200_dgac511-B44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0037-1613379","article-title":"Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use","volume":"89","author":"Abdollahi","year":"2003","journal-title":"Thromb Haemost"},{"issue":"3","key":"2022121716483093200_dgac511-B45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"6","key":"2022121716483093200_dgac511-B46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.contraception.2019.02.001","article-title":"Segesterone acetate\/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation","volume":"99","author":"Gemzell-Danielsson","year":"2019","journal-title":"Contraception"},{"issue":"3","key":"2022121716483093200_dgac511-B47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"issue":"5","key":"2022121716483093200_dgac511-B48","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1055\/s-0038-1641152","article-title":"Type of combined contraceptives, factor V Leiden mutation and risk of venous thromboembolism","volume":"118","author":"Hugon-Rodin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"2022121716483093200_dgac511-B49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.16666","article-title":"The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk","volume":"191","author":"Khialani","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2022121716483093200_dgac511-B50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5\u2005mg) and 17\u03b2-oestradiol (1.5\u2005mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"3","key":"2022121716483093200_dgac511-B51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH10-05-0327","article-title":"Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate\/17\u03b2-estradiol, compared with those of levonorgestrel\/ethinyl estradiol. A double-blind, randomised study","volume":"105","author":"Gaussem","year":"2011","journal-title":"Thromb Haemost"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac511\/47069135\/dgac511.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/1\/135\/48076766\/dgac511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/1\/135\/48076766\/dgac511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:49:14Z","timestamp":1671277754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/1\/135\/6696881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2022,12,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac511","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,9,13]]}}}